GlassScriptPhysician profile
Sarah Chang
NPI 1043942667
$3,395.45
in general payments reported to CMS, 2019-2025
17 companies · $1,260 in 2025
The $1,260 reported for 2025 was more than what 94% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $423 · 2023: $882 · 2024: $830 · 2025: $1,260.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,973.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,972.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $1,013.44 | 2022-2025 | Miebo, Xiidra, Infuse |
| Sun Pharmaceutical Industries INC. | $516.64 | 2022-2025 | Cequa |
| Alcon Vision LLC | $401.37 | 2022-2025 | Dailies Total1, Precision7, Precision 1 |
| Tarsus Pharmaceuticals, INC. | $308.26 | 2024-2025 | Xdemvy |
| Apellis Pharmaceuticals, INC. | $250.90 | 2023-2025 | Syfovre |
| Mallinckrodt Hospital Products INC. | $222.26 | 2023-2024 | Acthar |
| Dompe US, INC. | $134.65 | 2024-2025 | Oxervate |
| Johnson & Johnson Vision Care, INC. | $124.99 | 2025 | Acuvue |
| Genentech USA, INC. | $120.74 | 2023 | Vabysmo |
| Oyster Point Pharma, INC. | $113.71 | 2022 | |
| Carl Zeiss Meditec USA, INC. | $39.55 | 2024 | Cirrus Hd-Oct |
| Novartis Pharmaceuticals Corporation | $36.62 | 2022 | |
| Ani Pharmaceuticals, INC. | $27.61 | 2024 | Purified Cortrophin Gel |
| Visioneering Technologies, INC. | $27.00 | 2022 | |
| Abbvie INC. | $24.58 | 2025 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $19.58 | 2024 | |
| Coopervision INC. | $13.55 | 2025 | Myday Contact Lens |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Chang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.